InsidersTradesSigma
Follow the 翰宇药业 stock price and the full directors' dealings record of the company, a listed equity based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 翰宇药业 has logged 4 reports. Market capitalisation: €18.3bn. The latest transaction was reported on 2 June 2023 (Sale). Among the most active insiders: 曾少彬. The full history is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
翰宇药业是一家在健康和制药领域的公司，在 XSHE 市场上市。它专注于创新药物的开发和生产。